Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.
Ahmed S, Bosma N, Moser M, Ahmed S, Brunet B, Davies J, Doll C, Dueck DA, Kim CA, Ji S, Le D, Lee-Ying R, Lim H, McGhie JP, Mulder K, Park J, Ravi D, Renouf DJ, Schellenberg D, Wong RPW, Zaidi A. Ahmed S, et al. Among authors: ravi d. Curr Oncol. 2022 Mar 8;29(3):1796-1807. doi: 10.3390/curroncol29030147. Curr Oncol. 2022. PMID: 35323347 Free PMC article.
Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers-A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.
Mulder K, Lim H, Ravi D, Ahmed S, Brunet B, Davies J, Doll C, Dueck DA, Gordon V, Hebbard P, Kim CA, Le D, Lee-Ying R, McGhie JP, Park J, Renouf DJ, Schellenberg D, Wong RPW, Zaidi A, Ahmed S. Mulder K, et al. Among authors: ravi d. Curr Oncol. 2022 Apr 29;29(5):3160-3170. doi: 10.3390/curroncol29050257. Curr Oncol. 2022. PMID: 35621647 Free PMC article.
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G. Shi R, et al. Among authors: ravi d. Lung Cancer. 2020 Aug;146:78-85. doi: 10.1016/j.lungcan.2020.05.018. Epub 2020 May 21. Lung Cancer. 2020. PMID: 32521388